A diagnostic challenge is the persistence of minimal residual uptake (MRU)
A diagnostic challenge is the persistence of minimal residual uptake (MRU). monoclonal antibody rituximab. When carefully applied with appropriate supportive measures, these modern programs achieve a cure rate of approximately 90% in the average AYA patient, irrespective of clinical stage, which is the best result achievable in any aggressive lymphoid malignancy to date. The challenges … Read more